Ivemend (Fosaprepitant)

Fosaprepitant selectively blocks the neurokinin‑1 (NK1) receptor, preventing the neuropeptide substance P from binding. Substance P is a major trigger of the vomiting reflex; its inhibition reduces both the early (acute) and later (delayed) phases of chemotherapy‑induced nausea and vomiting.

The prescribed dose of Ivemend is determined by the treating physician. In clinical practice, a single intravenous dose of 150 mg is commonly administered shortly before chemotherapy, but exact dosing and timing are individualized based on the chemotherapy regimen and patient factors.

Safety of fosaprepitant in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To order Ivemend, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The primary oral alternative is aprepitant, another NK1 antagonist. Fosaprepitant offers a convenient single‑dose intravenous option, which can be advantageous for patients who cannot take oral medication or need rapid onset. Both agents share the same mechanism, but fosaprepitant avoids issues related to oral absorption and gastrointestinal tolerability.

Ivemend should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. Once reconstituted, use the solution promptly according to the manufacturer’s instructions.

The lyophilized powder is reconstituted with a suitable sterile diluent to the required concentration. The resulting solution is administered intravenously, typically over 15–30 minutes, shortly before the start of chemotherapy. Administration should follow institutional protocols for IV anti‑emetics.

Serious adverse events include hypersensitivity reactions such as rash, pruritus or anaphylaxis, significant elevations in liver enzymes, and rare cardiac events like QT‑interval prolongation. Patients should be monitored for signs of allergic reaction, liver dysfunction, and cardiac rhythm changes during and after infusion.

Ivemend is contraindicated in patients with known hypersensitivity to fosaprepitant or any component of the formulation. Caution is advised in severe hepatic impairment, in patients receiving strong CYP3A4 inhibitors, and in pregnant women unless the benefit outweighs the risk. Clinicians should assess each patient individually.